Go Pro
OTCMKTS:BIXT

Bioxytran Q1 2026 Earnings Report

Bioxytran logo
$0.02 +0.00 (+5.75%)
As of 11:32 AM Eastern

Bioxytran EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioxytran Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioxytran Announcement Details

Quarter
Q1 2026
Time
During Market Hours
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Bioxytran Earnings Headlines

The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.tc pixel
See More Bioxytran Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioxytran? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioxytran and other key companies, straight to your email.

About Bioxytran

Bioxytran (OTCMKTS:BIXT) is a development-stage biotechnology company focused on creating treatments for medical conditions associated with inadequate oxygen delivery to tissues. The company is developing therapies based on a proprietary nanobubble platform designed to transport and deliver oxygen in the body.

Bioxytran’s lead development program, BXT-25, is an investigational intravenous product intended to improve oxygenation in patients affected by ischemic stroke. The company has also described potential applications for its technology in other conditions involving tissue oxygen deprivation, although these programs remain subject to research, development and regulatory evaluation.

Bioxytran primarily operates as a biotechnology research and development company and does not appear to have an approved commercial product portfolio. Information about the company’s broader geographic operations and current leadership is limited in publicly available sources.

View Bioxytran Profile